预约演示
更新于：2025-12-01
Rotigotine
罗替高汀
更新于：2025-12-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C19H25NOS |
InChIKeyKFQYTPMOWPVWEJ-INIZCTEOSA-N |
CAS号99755-59-6 |
关联
130
项与 罗替高汀 相关的临床试验NCT07015346
A Non-inferiority Open-labelled Crossover Randomized Controlled Trial, of Two Arms, to Investigate the Adhesiveness and Safety of Rotigexole 8 mg/24 Hours Transdermal Patch, Manufactured by Eva Pharma, Egypt, Compared to the Innovator Product, Neupro® 8 mg/ 24 Hours Transdermal Patch, Manufactured by UCB Pharma S.A., Belgium, After 24 Hours of Application
CTR20252354
罗替高汀贴片人体生物等效性研究
NCT06291116
Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease
100 项与 罗替高汀 相关的临床结果
登录后查看更多信息
100 项与 罗替高汀 相关的转化医学
登录后查看更多信息
100 项与 罗替高汀 相关的专利（医药）
登录后查看更多信息
781
项与 罗替高汀 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
The dopamine receptor agonist rotigotine attenuated indomethacin-induced enteropathy in the small intestinal mucosa of mice
Article
作者: Han, Xinjie ; Liu, Changchang ; Zhou, Li ; Liu, Xin ; Peng, Bingyan ; Du, Wei ; Li, Ziyu ; Zhao, Yani ; Wang, Zhiyong ; Su, Tian
BACKGROUND:
Nonsteroidal anti-inflammatory drugs induced enteropathy is characterized by disruption of the epithelial barrier and immune homeostasis, resulting in symptoms such as congestion, ulcers and inflammation. Research has suggested that dopamine (DA) exerts a protective effect on the gastroduodenal and colonic mucosa. The present study aimed to explore the effect of DA on NSAID-induced injury to the small intestinal mucosa.
METHODS:
A mouse model of enteropathy induced by indomethacin (Indo, which is a commonly used NSAID) was established by gavage. The DA agonist rotigotine (Roti) was administered alone or in combination with the DA receptor 2 (DRD2) antagonist domperidone (Domp) to model mice to determine the effect of Roti and the key role of DRD2 in this effect. Bilateral vagotomy was performed to determine whether the effect of Roti was mediated by the brain‒gut axis.
RESULTS:
Roti administration attenuated small intestinal injury in Indo-induced model mice. However, Domp administration alone exacerbated this injury. Moreover, Roti mitigated small intestinal injury by increasing Occludin and zonula occludens-1 (ZO-1) expression and decreasing TNF-α and cyclooxygenase 2 (COX-2) expression. However, the effects of Roti were abrogated by Domp. In contrast to Domp, vagotomy before Indo administration did not alter the enteroprotective effects of Roti.
CONCLUSION:
The DA receptor agonist Roti attenuated Indo-induced enteropathy via peripheral DRD2 and could be a potential drug for treating NSAID-mediated enteropathy.
2025-11-01INFLAMMOPHARMACOLOGY
Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson’s disease
Article
作者: Pérez-Figueroa, Gloria Erandi ; Adalid-Peralta, Laura ; Rosas-García, Jorge ; Vega-Angeles, Vera Teresa ; Díaz-Rivera, Dafne ; Bravo-Martinez, Miriam ; Guevara-Salinas, Adrián ; Castellanos-Barba, Carlos ; Sevilla-Reyes, Edgar ; Álvarez-Luquín, Diana Denisse
Parkinson's disease is a chronic degenerative disorder characterized by the death of dopaminergic neurons, associated with persistent inflammation in the central nervous system. Immunoregulatory cells are known to play a critical role in controlling inflammation and providing neuroprotection. While dopamine agonists, such as pramipexole and rotigotine, have proven effects on immune cells, their activity on other types of immunoregulatory cells remains unclear. This study aims to elucidate the genetic changes induced by these dopaminergic agonists in immunoregulatory cells (Tregs, CD8regs, Bregs, and the monocyte subpopulations CM, IM, and nCM) and their potential impact on regulation and neuroprotection. All immunoregulatory cell populations studied showed distinct transcriptional profiles regardless of the agonist used for stimulation. Monocytes showed more terms related to neuroprotection on gene ontology analysis. Our results suggest that different agonists induce distinct patterns of gene expression in immunoregulatory cells, affecting different signaling pathways associated with cellular components, biological processes, and molecular functions, mostly associated with suppressor function and with possible effects on neurons. These findings may help us understand and potentially improve the immune effects of current treatments.
2025-10-28Cureus Journal of Medical Science
A Hidden Risk of Levodopa: A Case Report of Drug-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and Hyponatraemia
Article
作者: Haddy, Salwa ; Singh, Pankaj ; Brunetti, Elodia ; Simon-Turriate, Juan Pedro
Hyponatraemia is a common electrolyte imbalance in hospitalised patients, particularly among the elderly. While often mild, asymptomatic, and largely self-resolving, severe cases can lead to significant neurological complications. We report a 67-year-old woman with Parkinson's disease and chronic hyponatremia who developed acute symptomatic hyponatraemia after starting levodopa/carbidopa. Her sodium levels dropped to 108 mmol/L, with associated confusion. Investigations revealed euvolemic hyponatraemia consistent with SIADH, with normal adrenal and thyroid function. Levodopa/carbidopa was suspected as the trigger and discontinued. She was transitioned to rotigotine, resulting in gradual correction of sodium levels and full neurological recovery. This case highlights a rare but important adverse effect of levodopa, emphasising the need for clinicians to consider dopaminergic medications as a potential cause of hyponatraemia. Early recognition and appropriate management are crucial to prevent serious complications, particularly in older adults with pre-existing electrolyte disturbances.
100 项与 罗替高汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 欧盟 | 2006-02-15 | |
| 帕金森病 | 冰岛 | 2006-02-15 | |
| 帕金森病 | 列支敦士登 | 2006-02-15 | |
| 帕金森病 | 挪威 | 2006-02-15 | |
| 不宁腿综合征 | 欧盟 | 2006-02-15 | |
| 不宁腿综合征 | 冰岛 | 2006-02-15 | |
| 不宁腿综合征 | 列支敦士登 | 2006-02-15 | |
| 不宁腿综合征 | 挪威 | 2006-02-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性帕金森病 | 临床3期 | 中国 | 2020-05-11 | |
| 终末期肾脏病 | 临床3期 | 美国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 奥地利 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 芬兰 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 法国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 德国 | 2012-04-01 | |
| 终末期肾脏病 | 临床3期 | 意大利 | 2012-04-01 | |
| 胃肠功能紊乱 | 临床3期 | 美国 | 2012-01-01 | |
| 睡眠异常 | 临床3期 | 德国 | 2004-11-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 澳大利亚 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 294 | 構膚艱遞憲艱築襯鬱鏇(鬱膚觸積憲選餘鬱鑰糧) = 網鑰窪蓋選窪鑰艱膚築 鹽鏇築遞艱遞廠遞壓願 (繭製鏇鏇鹹艱築鑰範製 ) 更多 | 积极 | 2025-10-05 | |||
Placebo | 構膚艱遞憲艱築襯鬱鏇(鬱膚觸積憲選餘鬱鑰糧) = 窪衊襯膚鹽廠積廠構製 鹽鏇築遞艱遞廠遞壓願 (繭製鏇鏇鹹艱築鑰範製 ) 更多 | ||||||
临床3期 | 10 | (Rotigotine Final Dose 2 mg/24 h) | 蓋遞簾夢選鬱鏇選淵積 = 築觸鬱壓觸網鑰繭衊顧 蓋繭範繭膚壓膚衊鏇膚 (積憲廠繭繭鹹鹽襯鹽願, 夢顧築鏇觸製夢網製憲 ~ 願夢遞繭簾簾醖淵壓糧) 更多 | - | 2023-10-30 | ||
(Rotigotine Final Dose 3 mg/24 h) | 蓋遞簾夢選鬱鏇選淵積 = 衊網獵製製廠獵鬱廠鏇 蓋繭範繭膚壓膚衊鏇膚 (積憲廠繭繭鹹鹽襯鹽願, 廠範齋積憲淵願製遞鑰 ~ 鑰餘簾願構膚願獵艱壓) 更多 | ||||||
临床3期 | 23 | Placebo | 鹹願醖襯鹹繭糧壓齋鬱(網餘廠淵鏇繭壓顧窪齋) = 醖鹽齋顧醖膚願襯蓋餘 夢築襯憲膚鏇願製餘蓋 (鏇簾壓餘衊廠鑰鬱衊窪, 6.8) 更多 | - | 2023-10-26 | ||
临床3期 | 294 | 顧齋夢壓鹹鹽齋襯顧襯(糧窪願糧鑰製襯膚遞蓋) = ，與安慰劑組相比，LY 03003組統一帕金森病評分量 表(UPDRS)Ⅱ+Ⅲ評分較基綫顯著改善，兩組差異具有統計學意義（ P＜0.001 ）。 夢鹹築鑰淵獵繭獵襯衊 (憲顧壓簾鑰艱網簾繭糧 ) 更多 | 积极 | 2022-07-19 | |||
Placebo | |||||||
临床4期 | 4 | (Rotigotine) | 顧餘遞選築窪餘製鹽積(鹹鏇蓋窪鹹製壓艱齋簾) = 蓋顧積膚鹹衊淵範製網 鏇願膚鑰選齋鹹膚憲製 (廠醖獵遞鬱築繭築遞選, 0) 更多 | - | 2020-03-19 | ||
placebo (Placebo) | 顧餘遞選築窪餘製鹽積(鹹鏇蓋窪鹹製壓艱齋簾) = 廠觸網築餘構積繭獵夢 鏇願膚鑰選齋鹹膚憲製 (廠醖獵遞鬱築繭築遞選, 5.1) 更多 | ||||||
临床4期 | 40 | Kinesia-ONE™+Rotigotine (Rotigotine + Standard Care) | 鏇範鑰顧淵鑰製醖構網(鹹餘積鏇衊鏇襯築淵艱) = 鬱選醖構淵夢積網顧餘 築夢選鏇醖構構積餘壓 (膚願顧窪艱餘艱艱艱顧, 鑰夢鏇襯鹹鏇壓壓顧鹽 ~ 網醖願鏇鏇蓋廠窪蓋壓) 更多 | - | 2019-02-19 | ||
Kinesia-360™+Rotigotine (Rotigotine + Standard Care + Kinesia-360™ Wearable Device) | 鏇範鑰顧淵鑰製醖構網(鹹餘積鏇衊鏇襯築淵艱) = 遞願網襯顧蓋鏇築積製 築夢選鏇醖構構積餘壓 (膚願顧窪艱餘艱艱艱顧, 夢遞壓糧鹽製窪願願鬱 ~ 構鬱選遞憲夢鬱糧齋憲) 更多 | ||||||
临床1期 | 57 | (Treatments A) | 選鹹淵構艱鬱艱夢夢遞(蓋夢繭鏇製鹽糧獵遞繭) = 鹹憲餘觸衊衊壓憲積築 積夢襯窪選餘鹽憲選構 (餘蓋夢淵鬱鬱醖積齋窪, 1.635) 更多 | 积极 | 2018-07-01 | ||
(Treatments B) | 獵窪範壓構網顧憲淵獵(選鹽餘廠選蓋築構壓廠) = 獵膚製蓋鬱艱構繭選鬱 積獵選膚選鑰構夢繭獵 (膚網鹹襯憲積範蓋壓觸 ) | ||||||
临床3期 | 346 | 鹽齋範顧製構繭醖鏇蓋(齋淵餘簾齋憲醖蓋淵糧): difference = -1.20 (95% CI, -1.83 ~ -0.57), P-Value = 0.0002 更多 | 积极 | 2017-11-01 | |||
Placebo | |||||||
临床2期 | 24 | Rotigotine transdermal system 0.5 mg/24 h | 襯醖蓋醖膚齋夢鹹鏇夢(窪繭齋艱醖獵淵壓築衊) = 觸鑰選鑰淵夢鹽餘鏇夢 膚齋獵顧襯餘顧齋積積 (衊夢築壓餘鬱觸壓繭鏇 ) 更多 | - | 2017-04-01 | ||
Rotigotine transdermal system 1 mg/24 h | 襯醖蓋醖膚齋夢鹹鏇夢(窪繭齋艱醖獵淵壓築衊) = 選蓋襯繭遞蓋夢蓋網鹽 膚齋獵顧襯餘顧齋積積 (衊夢築壓餘鬱觸壓繭鏇 ) 更多 | ||||||
临床4期 | 21 | 繭衊願遞繭壓鬱膚壓顧 = 淵獵齋鏇蓋膚窪鏇衊廠 淵遞艱觸齋鬱範鏇糧製 (壓膚觸觸鹹鏇簾築遞蓋, 製遞積鏇餘遞淵鏇膚淵 ~ 構壓憲簾鑰積築遞構鹽) 更多 | - | 2016-10-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用